https://www.selleckchem.com/products/Fluvastatin-Sodium(Lescol).html White matter (WM) fractional anisotropy increased with age, corresponding to WM volume increases, while mean diffusivity (MD) showed biphasic patterns. The longitudinal trajectory of brain development in young rhesus monkeys follows typical maturation patterns seen in humans, but regional volumetric and MD changes are more dynamic in rhesus monkeys compared with humans, with marked decreases followed by "rebound-like" increases. © The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail journals.permissions@oup.com.BACKGROUND Phase 1 oncology trials are often regarded as a therapeutic option for patients. However, such claims have relied on surrogate measures of benefit, such as objective response. METHODS Using a systematic search of publications, we assessed the therapeutic value of phase 1 cancer trial participation by determining the probability that patients will receive active doses of treatments that eventually receive FDA approval or an NCCN guideline recommendation for their indication. ClinicalTrials.gov, Pubmed, ASCO reports, NCCN Guidelines and Drugs@FDA were searched between May 1, 2018 and July 31, 2018. All statistical tests were two-sided. RESULTS 1000 phase 1 oncology trials initiated between 2005 and 2010 and enrolling 32,582 patients were randomly sampled from 3229 eligible trials on ClinicalTrials.gov. A total of 386 (1.2%) patients received a treatment that was approved by the U.S. Food and Drug Administration for their malignancy at a dose delivered in the trial; including NCCN guideline recommendations, the number and proportion are 1168 (3.6%). Meta regression showed a statistically significantly greater proportion of patients receiving a drug that was ultimately FDA approved in biomarker trials (rate ratio = 4.49, 95%CI = 1.53 to 13.23, p = 0.006) and single-indication trials (rate ratio = 3.32, [1.21 - 9.15], p = 0.02; p